Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300577 | 0.93 | NTRK1 (0.42) | KMT2AALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL4287190 | 0.88 | NPSR1 (0.41) | KMT2AALDH1A1HTTLMNAPOLB | |
| SCHEMBL4292291 | 0.87 | KMT2A (0.42) | KMT2ASMN1; SMN2MEN1HPGDHSD17B10 | |
| SCHEMBL4287492 | 0.86 | MEN1 (0.41) | KMT2AMEN1HSD17B10 | |
| SCHEMBL4297014 | 0.85 | MEN1 (0.40) | KMT2AALDH1A1MEN1CYP3A4KDM4E | |
| SCHEMBL4296392 | 0.85 | MEN1 (0.42) | KMT2AMEN1 | |
| SCHEMBL4298836 | 0.85 | KMT2A (0.49) | KMT2AALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL4291810 | 0.85 | MEN1 (0.43) | KMT2AALDH1A1MEN1CYP3A4KDM4E | |
| SCHEMBL4296733 | 0.84 | MEN1 (0.40) | KMT2AALDH1A1SMN1; SMN2MEN1KDM4E | |
| SCHEMBL4287067 | 0.82 | MEN1 (0.48) | KMT2AALDH1A1SMN1; SMN2MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | KMT2A 1440/4885ALDH1A1 372/4885HTR1A 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.